002737SZSE

Announcement on the Investment to Establish a Wholly-Owned Subsidiary

Sunflower Pharmaceutical Group Co., Ltd.·March 31, 2026·2 pages

✨ AI Summary

Sunflower Pharmaceutical Group Co., Ltd. is investing 100 million RMB to establish a wholly-owned subsidiary, Hubei Pharmaceutical Co., Ltd. The purpose is to integrate business models and enhance operational efficiency within the medical field. This strategic move aims to improve resource allocation and overall company performance. The investment is self-financed and does not significantly alter the existing management or equity structure.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

I. Overview of External Investment

Sunflower Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company" or "this Company") has decided to use its own funds of 100 million RMB to invest in the establishment of a wholly-owned subsidiary, Hubei Pharmaceutical Co., Ltd. (hereinafter referred to as "Hubei Pharmaceutical"), which will ultimately be subject to the supervision of the relevant regulatory authorities.

This investment aims to establish Hubei Pharmaceutical, which will operate in the medical field, conduct business planning, and promote the integration of various business models, enhancing the company's operational efficiency and resource allocation.

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.